Search - tctmd.com

Displaying 241 - 260 of 671

Sort: Relevancy | Date

News Daily News

ADAPT-DES Analysis Reopens Debate Over Possible PPI, Clopidogrel Interaction

Caitlin E. Cox

October 28, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Daily News

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

Yael L. Maxwell

October 09, 2015

News Daily News

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Yael L. Maxwell

October 09, 2015

News Daily News

在PCI患者中切入部位和坎格雷洛之间没有相互作用

Caitlin E. Cox

October 06, 2015

News Daily News

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Caitlin E. Cox

October 06, 2015

News Daily News

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

Caitlin E. Cox

October 06, 2015

News Daily News

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

L.A. McKeown

September 21, 2015

News Daily News

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

L.A. McKeown

September 21, 2015

News Daily News

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

Yael L. Maxwell

September 18, 2015

News Daily News

RECLOSE-3: Cambiar a Clopidogrel a No Respondedores al Prasugrel Reduce la Mortalidad Post-PCI

Yael L. Maxwell

September 18, 2015

News Daily News

RECLOSE-3：对氯吡格雷无反应者改用普拉格雷可降低PCI术后死亡率

Yael L. Maxwell

September 18, 2015

Presentation

RECLOSE-3: Prasugrel in Clopidogrel Nonresponders Undergoing PCI

Presenter: R. Valenti

September 17, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Conference News ESC 2015

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Caitlin E. Cox

August 31, 2015

News Conference News ESC 2015

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Yael L. Maxwell

August 31, 2015

News Conference News ESC 2015

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

Caitlin E. Cox

August 31, 2015

Advertisement

ADAPT-DES Analysis Reopens Debate Over Possible PPI, Clopidogrel Interaction

Discussion Highlights Merits, Limitations of Small Trials

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

在PCI患者中切入部位和坎格雷洛之间没有相互作用

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

RECLOSE-3: Cambiar a Clopidogrel a No Respondedores al Prasugrel Reduce la Mortalidad Post-PCI

RECLOSE-3：对氯吡格雷无反应者改用普拉格雷可降低PCI术后死亡率

RECLOSE-3: Prasugrel in Clopidogrel Nonresponders Undergoing PCI

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content